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Abstract
To compare the efﬁcacy of two commercially available, alcohol-based antiseptic solutions for preparation and care of central venous
catheter (CVC) insertion sites, with and without octenidine dihydrochloride, a double-blind, randomized, controlled trial was under-
taken in the haematology units and in one surgical unit of two university hospitals. Adult patients with a non-tunnelled CVC were
randomly assigned to two different skin disinfection regimens at the insertion site: 0.1% octenidine with 30% 1-propanol and 45%
2-propanol, and as control 74% ethanol with 10% 2-propanol. Endpoints were (i) skin colonization at the insertion site; (ii) positive
culture from the catheter tip (‡15 CFU); and (iii) occurrence of CVC-associated bloodstream infection (deﬁned according to criteria
set by the CDC). Four hundred patients with inserted CVC were enrolled from May 2002 through April 2005. Both groups were simi-
lar in respect of patient characteristics and co-morbidities. Skin colonization at the CVC insertion site during the ﬁrst 10 days was sig-
niﬁcantly reduced by octenidine treatment (relative difference octenidine vs. control: 0.21; 95%CI: 0.11–0.39, p <0.0001). Positive
culture of the catheter tip was signiﬁcantly less frequent in the octenidine group (7.9%) than in the control group (17.8%): OR = 0.39
(95%CI: 0.20–0.80, p 0.009). Patients treated with octenidine had a non-signiﬁcant reduction in catheter-associated bloodstream infec-
tions (4.1% vs. 8.3%; OR = 0.44; 95%CI: 0.18–1.08, p 0.081). Side effects were similar in both groups. This randomized controlled trial
supports the results of two observational studies demonstrating octenidine in alcoholic solution to be a better option than alcohol
alone for the prevention of CVC-associated infections.
Keywords: Alcohol, bloodstream infection, central venous catheter, disinfection, octenidine dihydrochloride
Original Submission: 14 October 2008; Revised Submission: 5 February 2009; Accepted: 5 February 2009
Editor: M. Paul
Article published online: 17 August 2009
Clin Microbiol Infect 2010; 16: 600–606
10.1111/j.1469-0691.2009.02917.x
Corresponding author and reprint requests: A. F. Widmer,
Division of Infectious Diseases & Hospital Epidemiology, University
Hospital Basel, CH-4031 Basel, Switzerland
E-mail: awidmer@uhbs.ch
Introduction
The use of central venous catheters (CVCs) is associated
with a high risk of infectious complications [1–3]. In the USA
up to 80 000 episodes of nosocomial bloodstream infection
associated with CVCs (CA-BSIs) in intensive-care units are
reported each year [2,4]. The average rate of CA-BSIs in
neutropenic patients in ICUs ranges from 2–10/1000 to 14/
11000 catheter days in neutropenic patients [5]. The mortal-
ity attributable to these infections may exceed 25%, and the
associated increase in morbidity leads to a substantial rise in
health care expenditures [6–11].
Suppression of cutaneous colonization is an important
strategy for reducing CA-BSI; thus use of skin antiseptics
such as chlorhexidine is a CDC category IA recommenda-
tion [12]. The bispyridinamine octenidine dihydrochloride
(referred to as octenidine) is an antimicrobial effective
against most Gram-positive and Gram-negative bacteria
[13–15]. At low concentrations (0.1%), it shows excellent
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bactericidal and fungicidal, and moderate virucidal, activity
[16–18]. It displays minimal absorption (skin, mucous mem-
branes) and no systemic toxicity [19].
An aqueous solution containing octenidine and phenoxy-
ethanol has been shown to be safe for skin disinfection in
pre-term newborns [20]. Used for care of CVC insertion
sites in patients undergoing bone marrow transplantation,
this antiseptic decreased bacterial density at the insertion
site over time [21]. In an earlier clinical trial a residual or
remnant effect of octenidine combined with propanol in
microbial skin decontamination over a 24 h period was
shown [22]. The objective of this study was therefore to
evaluate further the preventive impact and tolerability of
octenidine for the preparation and care of CVC insertion
sites.
Methods
Design overview
A double-blind, randomized, controlled trial was conducted
to compare the efﬁcacy of two alcohol-based skin disinfec-
tants, one additionally containing the substance octenidine.
Setting and participants
The study was carried out from 2002 through 2005 in the
haematology units of University Medical Center Freiburg (FR;
Freiburg, Germany) and University Hospital Basel (BS; Basel,
Switzerland) and in one surgical unit (BS). Both institutions
are tertiary care facilities. The study was approved by both
local ethics committees and entered into the clinical trials
registry of the University Medical Center Freiburg
(UKF000502, http://www.zks.uni-freiburg.de/uklreg/php/show_
study.php?STUDIEN_ID=000502&kindOfSearch=frei=DE) [23].
Subsequently the trial was registered at ClinicalTrials.gov (Iden-
tiﬁer: NCT00515151).
Adult inpatients scheduled to receive a non-tunnelled
CVC for an expected period of 5 or more days were asked
for their informed consent. Exclusion criteria were known
sensitization to the proposed antiseptics, administration of
antimicrobial drugs for therapy (not prophylaxis) <1 week
prior to catheterization, pre-existing BSI (i.e. fever and/or
other signs of infection and positive blood culture), and
existing burns. In addition, patients participating in a clinical
trial of other antiseptics within a period of 4 weeks were
excluded. Patients who received a new catheter after the fol-
low-up period, i.e. at the earliest 30 days after removal of
the ﬁrst catheter, were permitted to enrol again.
Case report forms and corresponding patient ﬁles in 10%
of all cases were checked by an independent monitor.
Randomization and interventions
The randomization code was produced by the independent
Center for Clinical Studies (FR) using a computerized
random-number generator. The study centre was used as a
stratiﬁcation factor and block randomization with randomly
varying block length was performed. The randomization was
realised using closed envelopes, ensuring that the sequence
was concealed before patients entered the trial. The patients,
the staff administering the interventions, the microbiology
laboratory, and all the investigators assessing the outcomes
were blinded to the assignment. Bottles containing the disin-
fectants were not distinguishable and were coded in random
sequence. Both solutions were colourless with a predomi-
nantly alcoholic odour.
After obtaining their consent, patients were enrolled and
randomly assigned to two different commercially available
skin disinfection regimens: 0.1% octenidine with 30% 1-propanol
and 45% 2-propanol (referred to as the octenidine group)
and 74% ethanol with 10% 2-propanol (referred to as the
control group). Before catheterization, the entry site was
disinfected with the assigned solution over an area of
>200 cm2 for at least 1 min. After insertion, which was per-
formed under sterile barrier precautions according to a stan-
dard protocol, the catheter was dressed with sterile gauze
or a semi-permeable transparent dressing. During the change
of dressings, the assigned solution was also used for care of
the entry site following a standard protocol.
Outcomes and follow-up
The primary outcome variables, as per study protocol, were
(i) skin colonization at the insertion site, (ii) positive culture
from the catheter tip (‡15 CFU), and (iii) occurrence of
CVC-associated bloodstream infection (according to CDC
deﬁnitions).
1 Quantitative skin cultures were obtained before insertion
and at regular intervals (3 ± 1 days) during dressing change
from a 6 · 4 cm area of skin around the catheter insertion
site using a sterile template [24]. A sterile, moistened cot-
ton applicator was swabbed around the insertion site and
across the surrounding 24 cm2 area. The applicator was
placed in a tube containing 1.0 mL of 0.01 M phosphate-
buffered saline and taken to the laboratory. After vortex
mixing and diluting (1:10), aliquots of 0.1 mL of the suspen-
sion and of the dilution and 0.01 mL of the dilution only
were plated onto blood agar plates. Colonies were
counted after incubation at 35C for 48 h and the mean
value (CFU/24 cm2) was calculated.
2 After removal, the CVC tip was cultured by the roll-plate
technique. Colonization was deﬁned as ‡15 CFU [25].
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Results were standardized for a 5 cm segment of the cath-
eter by dividing the CFU count by actual length of the
CVC tip in cm and multiplying by ﬁve.
3 CVC-associated (primary), laboratory-conﬁrmed blood-
stream infection (CA-BSI) was deﬁned according to CDC
criteria [26] and observed up to 2 days after catheter
removal or, in cases of transfer of the patient to another
ward or hospital before catheter removal, up to 2 days
after the end of treatment with the study medication
(days at risk). Catheter-related (CR)-BSI was concluded
if, in addition to the criteria for CA-BSI, the bacterial
species isolated from blood and catheter tip cultures
matched.
Additionally, as exploratory analyses, interactions between
treatment and patients’ diagnosis/centre were investigated
with respect to the different endpoints.
Statistical analysis
Data were analysed according to a statistical analysis plan,
which was pre-speciﬁed and signed before the code was bro-
ken, using STATISTICAL ANALYSIS SYSTEM version 8 (SAS, Cary,
NC, USA).
Treatments were compared with respect to three efﬁcacy
criteria: (i) skin colonization within the ﬁrst 10 days after
CVC insertion, (ii) positivity of the catheter tip, (iii) occur-
rence of CVC-associated BSI. A 10-day analysis was chosen
because the main source of colonization in this time-frame is
the skin, with extraluminal bacterial spread alongside the
catheter. If there was no difference between treatment
groups with respect to criterion (i), it was assumed that
there was also no difference with respect to criteria (ii) and
(iii). Therefore, statistical tests (two-sided alpha = 5%) for
comparison of the treatment groups with respect to the
three efﬁcacy criteria were performed in the a-priori speciﬁed
sequence. Thus, no alpha correction of the individual tests
was necessary.
Sample size calculation was performed in order to show a
relevant difference with respect to criterion (ii). The
expected probability of a positive catheter tip was 20% in
the control group and 10% in the octenidine group. To show
this difference with a two-sided test (alpha = 5%) with a
power of 80%, a sample size of 400 patients was calculated.
With respect to criterion (i), a larger difference was
expected.
The efﬁcacy analyses were performed according to the
intention-to-treat principle, including all randomized patients
for whom the respective criteria were available. All
patients who received the study drug at least once were
included in the safety analysis. For the analysis of criterion
(i), the mean of the logarithm of the CFU values measured
within the ﬁrst 10 days was calculated. The effect of treat-
ment on this outcome was analysed with a linear regres-
sion model including centre and diagnosis as covariate for
adjustment. The effect was tested with alpha = 5% using
type III sum of squares. To quantify the effect, the relative
difference between treatment groups was calculated as the
difference of the adjusted means of the logarithm of the
CFU values from this model, transformed with the expo-
nential function, with 95% conﬁdence interval (CI). For the
analysis of criteria (ii) and (iii), logistic regression was used
including treatment and centre as covariates. The effect
was tested with alpha = 5% using the Wald test. To quan-
tify the effect, the odds ratio (OR) was calculated with
95% CI.
An interim analysis was undertaken after the randomiza-
tion of 258 patients in order to allow termination of the
study if no difference in efﬁcacy between treatment types
would be expected. For this purpose, the conditional power
for criterion (i) was calculated [27]. All the clinical investiga-
tors were fully blinded to the results of this analysis except
the conclusion that the study would be continued. Since this
analysis was not intended to conclude superiority of one of
the treatment arms no alpha-adjustment in the ﬁnal analysis
was necessary.
Results
Four hundred patients were enrolled from May 2002
through April 2005 (Fig. S1). In 11 patients, none of the
criteria (i)–(iii) could be analysed because no skin sample,
catheter tip and information on BSI were available.
Comparison of groups
Patients were under surveillance for BSI until 2 days after
catheter removal (octenidine group: 155; control group:
147), or until 2 days after study treatment was stopped
before catheter removal (39 vs. 46). The total number of
days at risk for BSI was 2760 in the octenidine group, and
2537 in the control group.
Both groups were similar regarding patient characteristics
(Table 1). Patient diagnoses differed between centres since
BS also randomized patients undergoing cardiothoracic
surgery (181 of 246 patients), while all patients at FR were
haemato-oncological patients. Twelve patients were random-
ized twice with at least a 30-day interval before re-randomi-
zation. A sensitivity analysis showed no relevant differences if
the patient’s second course was excluded from the dataset
(Tables S4 and S5).
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Skin colonization
Three hundred sixty ﬁve patients with at least one sample
after catheter insertion could be included in the analysis
(Fig. S1). Skin colonization at the CVC insertion site during
the ﬁrst 10 days was signiﬁcantly reduced by octenidine
treatment (Table 2).
The size of the effect on skin colonization varied between
patient groups (according to diagnosis and centre). However,
this difference was not signiﬁcant (Table S2).
Catheter tip colonization
Positivity of the catheter tip was signiﬁcantly lower in the
octenidine group (n = 13; 7.9%) vs. control (n = 28; 17.8%)
(Table 2). With 5.1 positive catheter tips per 1000 catheter
days the overall incidence in the octenidine group was
noticeably lower than in the control group (11.3 positive
catheter tips per 1000 catheter-days; log rank test, p 0.009).
The reduction in the rate of positive catheter tips (octeni-
dine vs. control) varied between haematological patients and
surgical patients in FR (not signiﬁcant, Table S2).
Catheter-associated bloodstream infections
There were fewer laboratory-conﬁrmed CA-BSIs in the
octenidine group (n = 8; 4.1%) than in the control group
(n = 16; 8.3%) (Table 2).
With 2.9 CA-BSIs per 1000 days at risk, the overall inci-
dence in the octenidine group was noticeably lower than
that in the control group (6.3 CA-BSIs per 1000 days at risk;
log rank test, p 0.051). The Kaplan-Meier estimates of BSI
rates over time are displayed in Fig. S2.
TABLE 1. Patient characteristics
Octenidine goup Control group
Number of patients 201 199
Centre (FR/BS)a 77/124 77/122
Age (25% quantile/median/75%
quantile)
47/59/68 48/59/70
Sex (female/male) 66/135 70/129
Haemato-oncological patients
(FR/BS)//surgical patients (BS)a
77/33//91 77/32//90
Haematopoietic stem cell
transplantation
69 68
Duration of hospitalization before
catheterization (£1 day/2–4
days/‡5 days)
146/32/23 138/43/18
Duration of catheterization (days)
(25% quantile/median/75%
quantile)
3/10/24
(3 missing)
3/8/21
(4 missing)
Number of swabs (25%
quantile/median/
75% quantile)
1/2/5 1/2/4
Catheter type (antimicrobially
coatedb/uncoated)
153/48 154/43
(2 missing)
Catheter insertion site
(V. jugularis/V. subclavia)
167/34 159/38
(2 missing)
Neutropenia (yes/no) 113/84
(4 missing)
112/78
(9 missing)
Total parenteral nutrition
(yes/no)
59/135
(7 missing)
49/139
(11 missing)
Blood transfusion (yes/no) 153/41
(7 missing)
143/45
(11 missing)
aFR, study centre Freiburg; BS, study centre Basel.
bFirst generation chlorhexidine/silver sulfadiazine coated catheters were used in
all surgical patients (181) and in 126 of 219 haemato-oncologic patients.
TABLE 2. Quantitative skin cultures during the ﬁrst 10 days after catheter insertion, positive catheter tip culturesa and
CA-BSIb; comparison between octenidine group and control groupc
Treatment comparison (Octenidine vs. Control)
Number of patients Adjusted mean of CFU 95%-CI Relative difference of CFU 95%-CI p-value
Quantitative skin cultures Control 178 100.0 [64.5155.1] 0.21 [0.11,0.39] <0.0001
Octenidine 187 21.0 [13.7,32.2]
Treatment comparison (Octenidine vs. Control)
Number of patients
Patients with positive catheter
tip No. (%) Odds Ratio 95%-CI p-value
Pos. catheter tip culturea Control 157 28 (17.8) 0.39 [0.20,0.80] 0.009
Octenidine 165 13 (7.9)
Treatment comparison (Octenidine vs. Control)
Number of patients Patients with CA-BSIb No. (%) Odds Ratio 95%-CI p-value
CA-BSIb,d Control 193 16 (8.3) 0.44 [0.18,1.08] 0.081
Octenidine 194 8 (4.1)
a(‡15CFU/5 cm).
bCatheter-associated bloodstream infections.
cAdjusted for centre and diagnosis (haem/onc Freiburg, haem/onc Basel, surgical Basel).
dDue to the small number of events exact logistic regression analysis was used.
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All BSIs occurred in haemato-oncological patients, result-
ing in incidence densities in this population of 3.6 BSIs per
1000 days at risk in the octenidine group (n = 106), and 7.9
CA-BSIs per 1000 days at risk in the control group
(n = 104). Of the 24 BSIs 22 occurred in the haemato-
oncology unit in FR (Table S2).
CR-BSIs occurred in four cases (all in the control group:
three caused by coagulase- negative staphylococci and one
by Staphylococcus aureus; Fisher’s exact test, p 0.12). In one
patient with BSI caused by a coagulase-negative staphylo-
coccus no catheter tip was available for analysis (octenidine
group).
Microbiological results
For isolated microorganisms see Table S1. A detailed illustra-
tion of microorganisms involved in CVC tip colonization and
BSI is given in Table S3.
Side effects
No systemic side effects were observed in either group.
Local effects (mainly skin irritation/burning) in patients who
received the study medication at least once showed no sig-
niﬁcant differences between the two groups (Table 3).
Five patients died, either while receiving the intervention
under study or during follow-up (octenidine: four; control:
one). However, these deaths originated from the underlying
diseases and were not related to the antiseptics used.
Discussion
This is the ﬁrst RCT evaluating the efﬁcacy of octenidine in
preventing catheter colonizations and CA-BSIs. Octenidine/
propanol signiﬁcantly reduced bacterial density at the cathe-
ter insertion site and colonization of the catheter tip and
lowered the incidence of CA-BSI in comparison with alcohol
(ethanol/propanol) alone. The residual effect of octenidine -
similar to that of chlorhexidine - seems to be the most likely
explanation of the main effect [19]. Octenidine has very little
cytotoxic effect in vitro and is registered even for newborns,
in contrast to chlorhexidine. Skin irritation and burning were
commonly seen in this study. However, the equal occurrence
of side-effects with and without octenidine provides evidence
that the alcohol rather than octenidine was responsible for
the phenomena.
Limitations should be mentioned. ICU patients were not
included in the study despite having a high risk for CA-BSIs.
However, haematology patients are similarly at high risk, and
the average at period of catheterization is longer than in ICU
patients. About 20% of the catheters were not cultured,
which may have biased the results, but the non-cultured CVC
tips were equally distributed within the treatment groups and
the laboratory was blinded to catheter allocation.
The frequency of CA-BSIs among the patients of this trial
is in accordance with data from systematic surveillance
studies [5]. Of all CA-BSIs four cases were classiﬁed as
CR-BSIs (microorganisms on catheter tip matching those in
blood culture). Three out of four microorganisms were coag-
ulase-negative staphylococci. As molecular analyses were not
applied, some CR-BSIs may have been incorrectly classiﬁed.
General strategies to prevent CA-BSIs include the use of
full barrier precautions during insertion [28], prospective
surveillance and multifaceted prevention activities including
the use of chlorhexidine/alcohol [29,30], the currently rec-
ommended ﬁrst-line antiseptic for catheter care in the USA
and UK [31,32].
In conclusion, this RCT demonstrated superior activity of
octenidine/propanol compared to alcohol alone, supporting
the results of independent observational investigations
[21,22]. The similar in vitro activities of octenidine and chlorh-
exidine suggest that octenidine might be as effective as chlorh-
exidine in practice. However, only a comparative trial can
answer the question whether octenidine would be at least as
effective for preventing catheter colonization and CA-BSIs.
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